Thursday, January 28, 2021

Global – 100,200,000/2,200,000; USA – 25,500,000/428,000 Tedros called me up and aske me to help him connect with the Biden people, i.e. Sec Becerra, Jeff Zients, the VP, etc. Stewart Simonson willing to help me since I am ultra busy. Had confidential conversation with the Janssen people – Paul Stoffels et al about the Ad26 vaccine data. Not that great. 77% VE in USA and ~50% in RSA. Will get more details later. Data better against severe disease but this will be a messaging problem. Novavax and Janssen came out with their embargoed (until tomorrow) results of their trials: Novavax phase 3 in UK – 90% VE; Phase 2b in RSA – 50% VE. Janssen phase 3 in USA/RSA/Brazil - 72% VE at 28 days (a 1 dose vaccine); 85% VE against severe disease; 57% VE in mod/severe disease in RSA at 28 days and 88% VE with severe disease in RSA Much press activity and emphasis on the fact that antigenic variation has clinical consequences. Also, with both vaccines, good news for the global supply PRESS: Good Morning America (ABC) with George Stephanopoulos; NPR Morning Edition with Sarah McCammon;